Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 1/20 | 0.77 |
| ▸ | LDLR | P01130 | 1/20 | 0.65 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.63 |
| ▸ | GAA | P10253 | 5/20 | 0.56 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.55 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.55 |
| ▸ | ATP1A1 | P05023 | 4/20 | 0.50 |
| ▸ | ATP1B1 | P05026 | 4/20 | 0.50 |
| ▸ | ATP1A3 | P13637 | 4/20 | 0.50 |
| ▸ | ATP1B2 | P14415 | 4/20 | 0.50 |
| ▸ | ATP1A2 | P50993 | 4/20 | 0.50 |
| ▸ | ATP1B3 | P54709 | 4/20 | 0.50 |
| ▸ | FXYD2 | P54710 | 4/20 | 0.50 |
| ▸ | ATP1A4 | Q13733 | 4/20 | 0.50 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24418677 | 0.88 | HPGDS (0.62) | HPGDSLDLRPCSK9CYP1A2CYP3A4 | |
| SCHEMBL2365544 | 0.87 | HPGDS (1.00) | HPGDSLDLRPCSK9CYP1A2CYP3A4 | |
| SCHEMBL2835874 | 0.84 | HPGDS (0.67) | HPGDSLDLRPCSK9CYP1A2CYP3A4 | |
| SCHEMBL12721184 | 0.83 | CYP1A2 (0.63) | HPGDSLDLRPCSK9CYP1A2CYP3A4 | |
| SCHEMBL8453399 | 0.81 | HPGDS (0.58) | HPGDSLDLRPCSK9CYP1A2CYP3A4 | |
| SCHEMBL11515528 | 0.80 | HPGDS (0.53) | HPGDSLDLRPCSK9CYP1A2CYP3A4 | |
| SCHEMBL2837450 | 0.78 | HPGDS (0.76) | HPGDSLDLRPCSK9CYP1A2CYP3A4 | |
| SCHEMBL8306426 | 0.78 | HPGDS (0.54) | HPGDSLDLRPCSK9CYP1A2CYP3A4 | |
| SCHEMBL3958498 | 0.78 | CYP1A2 (0.61) | HPGDSLDLRPCSK9CYP1A2CYP3A4 | |
| SCHEMBL532551 | 0.78 | CYP1A2 (1.00) | HPGDSLDLRPCSK9CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11839140-B2 | Metal complexes comprising diazabenzmidazolocarbene ligands and the use thereof in OLEDS | UDC IRELAND LIMITED (IE) | 2023-12-05 | — | — | US | disclosed |
| US-11839140-B2 | Metal complexes comprising diazabenzmidazolocarbene ligands and the use thereof in OLEDS | UDC IRELAND LIMITED (IE) | 2023-12-05 | — | — | US | disclosed |
| US-20230026258-A1 | Metal Complexes Comprising Diazabenzmidazolocarbene Ligands and the Use Thereof in OLEDS | UDC IRELAND LTD (IE) | 2023-01-26 | — | — | US | disclosed |
| US-9850268-B2 | Metathesis catalysts and methods thereof | TRUSTEES OF BOSTON COLLEGE (US) | 2017-12-26 | — | — | US | disclosed |
| US-9701702-B2 | Metathesis catalysts and methods thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2017-07-11 | — | — | US | disclosed |
| US-20160229877-A1 | METATHESIS CATALYSTS AND METHODS THEREOF | NATIONAL SCIENCE FOUNDATION | 2016-08-11 | — | — | US | disclosed |
| US-9206211-B2 | Metathesis catalysts and methods thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2015-12-08 | — | — | US | disclosed |
| US-9067919-B2 | Use of dibenzofurans and dibenzothiophenes substituted by nitrogen-bonded five-membered heterocyclic rings in organic electronics | BASF SE (DE) | 2015-06-30 | — | — | US | disclosed |
| US-20140316088-A1 | METATHESIS CATALYSTS AND METHODS THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2014-10-23 | — | — | US | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1678185-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMA CO LTD (JP) | 2008-10-08 | — | — | EP | disclosed |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | OTSUKA PHAMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| US-4164480-A | POLYMER STABILIZERS | EASTMAN KODAK COMPANY (US) | 1979-08-14 | — | — | US | disclosed |
| US-4105631-A | MULTICHROMOPHORIC ULTRAVIOLET STABILIZERS AND THEIR USE IN ORGANIC COMPOSITIONS | EASTMAN KODAK COMPANY (US) | 1978-08-08 | — | — | US | disclosed |
| US-4043973-A | PIGMENTS, COLORANTS, FILLERS, REINFORCING AGENTS | EASTMAN KODAK COMPANY (US) | 1977-08-23 | — | — | US | disclosed |
| US-3939115-A | OXADIAZOLES | EASTMAN KODAK COMPANY (US) | 1976-02-17 | — | — | US | disclosed |
| US-3936419-A | Multichromophoric ultraviolet stabilizers and their use in organic compositions | EASTMAN KODAK COMPANY (US) | 1976-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | HPGDS 4351/4885LDLR 915/4885PCSK9 4873/4885 |
| US-20230026258-A1 | Metal Complexes Comprising Diazabenzmidazolocarbene Ligands and the Use Thereof in OLEDS | OCIAD1, OCIAD2, DRD2 | HPGDS 3245/4885LDLR 1757/4885PCSK9 4362/4885 |
| US-20160229877-A1 | METATHESIS CATALYSTS AND METHODS THEREOF | CYP51A1, SQLE, MOGAT2 | HPGDS 2919/4885LDLR 3465/4885PCSK9 1275/4885 |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | NR2C2, NR0B2, NR4A2 | HPGDS 4095/4885LDLR 2136/4885PCSK9 4880/4885 |
| US-20140316088-A1 | METATHESIS CATALYSTS AND METHODS THEREOF | CYP51A1, SQLE, MOGAT2 | HPGDS 2919/4885LDLR 3465/4885PCSK9 1275/4885 |
| US-11839140-B2 | Metal complexes comprising diazabenzmidazolocarbene ligands and the use thereof in OLEDS | OCIAD1, OCIAD2, DRD2 | HPGDS 3245/4885LDLR 1757/4885PCSK9 4362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.